Tagged with Investment

USA David H. Crean, Ph.D., Managing Partner at Cardiff Advisory, provides his insights on the potential impact of the US Federal Trade Commission (FTC)’s antitrust policies on biopharmaceutical mergers and acquisitions. Crean expects to see a continuation of 2023’s strong start to M&A and questions whether the FTC’s newly-aggressive approach will…

Hong Kong As managing director of the CR-CP Life Science Fund, whose shareholders, CR Group and CP Group, are on the Fortune Global 500 List, Da Liu leads investments in life sciences companies globally, especially those in emerging sectors such as RNA therapeutics and cancer screening. In conversation with PharmaBoardroom, Liu discusses…

Hong Kong Tech entrepreneur and investor Duncan Chiu has long been committed to developing local technology and innovation in Hong Kong. He discusses the current blueprint for advancing life sciences, advanced manufacturing, AI, big data and FinTech in the region and the need for government involvement to incentivise investment.   Historically, we…

Belgium Belgium’s Flanders region is a hotbed of biotech excellence, with numerous examples of university spin-offs being translated into commercial-stage companies and many of those later acquired by Big Pharma. Wouter Piepers of cluster organisation flanders.bio outlines the fundamentals behind this success story, and what potential future investors in Belgian biotech…

Hong Kong Professor Michael Yang of City University of Hong Kong (CityU) introduces the ‘HK Tech 300‘ programme he oversees, the largest university-based entrepreneurship programme in Asia. Drawing on his own experience as co-founder of Prenetics and Cellomics, biotech companies based on technologies developed in his laboratory at CityU, Professor Yang assesses…

Hong Kong Hong Kong’s Secretary for Innovation, Technology and Industry since July 2022, Professor Dong SUN is a pioneer in robotic manipulation of biological cells and robot control, whose research has led to breakthroughs in the use of robotics combined with various micro-engineering tools. Now with responsibility for developing Hong Kong into…

Belgium Karel van de Sompel of GIBBIS – the pluralistic federation of the public and private social-profit healthcare sector within the Brussels area – outlines the scope and aims of the organisation, the learnings from his near-four decades at Pfizer that can be applied in this new role, and some of…

Hong Kong Former chief executive of the Hong Kong Special Administrative Region (HKSAR) Leung Chun-ying (CY Leung) discusses recent science and technology initiatives like the new Hong Kong University of Science and Technology campus in Guangzhou and the Hong Kong-Shenzhen Innovation and Technology Park, which is set to further foster cooperation between…

Switzerland Taken from the recently published Swiss Biotech Report 2023, these figures cover major public and private financing transactions in Swiss biotech in the past year; major financing categories; capital investments in Swiss biotech companies; revenues, R&D expenses, profit/loss and liquidity; as well as well as the total number of biotech…

UAE Dr Ibtesam Al Bastaki, director of healthcare investment at the Dubai Health Authority (DHA) describes how healthcare investment is flowing into the Emirate via both pure investments and public-private partnerships (PPPs) and the impact of a range of other topics including screening programs, digital health, and healthcare tourism.   PPP…

China A roundup of some of the most significant recent stories from the Chinese pharmaceutical industry, including a slate of international investment which seems to suggest that – despite ongoing political tensions – China remains an attractive market for multinational pharma.   AstraZeneca defies geopolitics to bet on China – Financial…

UK The latest news from UK healthcare and the life sciences, including a record rise in the number of people using private healthcare services due to significant strains on the National Health Service (NHS); reaction to the government’s latest Life Science Plan; and the Medicines and Healthcare products Regulatory Agency (MHRA)’s…